Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia
J. Clin. Invest. Iwona Konieczna, et al. 118:853 doi:10.1172/JCI33742 [Go to this article.]

Figure 2
ICSBP bound the PRDI cis element in a tyrosine phosphorylation–dependent manner. (A) IVT WT ICSBP is tyrosine phosphorylated. IVT WT or Y-mut ICSBP was evaluated for tyrosine phosphorylation with or without treatment with recombinant Yop-PTP. Tyrosine phosphorylation of IVT ICSBP was decreased by this treatment, and Y-mut ICSBP was not tyrosine phosphorylated under either condition. (B) ICSBP binds the PRDI cis element in vitro in a tyrosine phosphorylation–dependent manner. IVT WT and Y-mut ICSBP were used in EMSA with a probe representing the PRDI consensus, with or without pretreatment with Yop-PTP. Y-mut ICSBP bound this probe with or without Yop treatment. In contrast, only Yop-treated WT ICSBP interacted with this probe in EMSA.